Samuel T. Wilkinson, MD
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
- 15Articles
- 121.7KReads1
- 2015–2026Active
- 84Collaborators
- 631Citations2
About
Samuel T. Wilkinson, MD, is affiliated with the Yale Depression Research Program in the Department of Psychiatry at Yale School of Medicine. From 2015 to 2026, Wilkinson has published extensively on major depressive disorder, bipolar disorder, and posttraumatic stress disorder, with a focus on treatments such as ketamine, esketamine, electroconvulsive therapy, and psychotherapy. Research topics also include suicide prevention, Alzheimer's disease, and complementary and alternative medicine. His work often explores clinical outcomes, safety, and treatment response in patients with treatment-resistant depression and comorbid conditions.
Publications
Ketamine as a Clinical Treatment for Mood Disorders
July 24, 2018
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
